Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
What Alkem files
- Others96
- Investor Meet62
- Updates42
- Important22
- PPTs11
- Board Meeting11
Alkem Laboratories has launched Renocia Exo™, India’s first patented Ginsenoside Exosome-based hair growth serum. This advanced regenerative therapy targets hair follicle vitality, scalp health, and cellular signalling pathways, strengthening the company's dermatology portfolio for managing rising hair loss concerns.
Alkem Laboratories Limited has informed the Exchange about Intimation under Regulation 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 ( SEBI LODR Regulations ) - Outcome of the 52nd Annual General Meeting of the Company and Disclosure of voting results thereat.
Alkem Labs reported Q1 FY27 revenue of INR 3,740 Cr (+11% YoY), with India sales up 10.3% and International up 16%. EBITDA margin was 20.5%, while net profit degrew 21.7% due to taxation. The company outperformed the Indian pharma market by 100 bps. Management expects ~12% India growth for FY27,...
Alkem Laboratories Limited has informed the Exchange regarding Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer s Report on e-voting (remote e-voting and e-voting at the Meeting)
Alkem Laboratories Limited's Q1FY27 Earnings Conference Call audio recording is now accessible on the company's investor relations website.